TY - JOUR T1 - Year-long COVID-19 infection reveals within-host evolution of SARS-CoV-2 in a patient with B cell depletion JF - medRxiv DO - 10.1101/2021.10.02.21264267 SP - 2021.10.02.21264267 AU - Veronique Nussenblatt AU - Allison E Roder AU - Sanchita Das AU - Emmie de Wit AU - Jung-Ho Youn AU - Stephanie Banakis AU - Alexandra Mushegian AU - Christopher Mederos AU - Wei Wang AU - Matthew Chung AU - Lizzette Pérez-Pérez AU - Tara Palmore AU - Jennifer N. Brudno AU - James N. Kochenderfer AU - Elodie Ghedin Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/05/2021.10.02.21264267.1.abstract N2 - Background B-cell depleting therapies may lead to protracted disease and prolonged viral shedding in individuals infected with SARS-CoV-2. Viral persistence in the setting of immunosuppression raises concern for viral evolution.Methods Amplification of sub-genomic transcripts for the E gene (sgE) was done on nasopharyngeal samples over the course of 355 days in a patient infected with SARS-CoV-2 who had previously undergone CAR T cell therapy and had persistently positive SARS-CoV-2 nasopharyngeal swabs. Whole genome sequencing was performed on samples from the patient’s original presentation and 10 months later.Results Over the course of almost a year, the virus accumulated a unique in-frame deletion in the amino-terminal domain of the spike protein, and complete deletion of ORF7b and ORF8, the first report of its kind in an immunocompromised patient. Also, minority variants that were identified in the early samples—reflecting the heterogeneity of the initial infection—were found to be fixed late in the infection. Remdesivir and high-titer convalescent plasma treatment were given, and the infection was eventually cleared after 335 days of infection.Conclusions The unique viral mutations found in this study highlight the importance of analyzing viral evolution in protracted SARS-CoV-2 infection, especially in immunosuppressed hosts, and the implication of these mutations in the emergence of viral variants.Summary We report an immunocompromised patient with persistent symptomatic SARS-CoV-2 infection for 335 days. During this time, the virus accumulated a unique in-frame deletion in the spike, and a complete deletion of ORF7b and ORF8 which is the first report of its kind in an immunocompromised patient.Competing Interest StatementDr. Jennifer Brudno is on the scientific advisory board for Kyverna Therapeutics, Inc. This is an unpaid position. Dr. James Kochenderfer: Research funding and patent royalties from Kite Pharma, a Gilead Company Clinical TrialNCT02659943Funding StatementThis work was funded in part by the Division of Intramural Research (DIR) at the National Institute of Allergy and Infectious Diseases of the NIH. We thank the Department of Laboratory Medicine staff for processing clinical specimens and providing technical assistance. This work utilized the computational resources of the NIH HPC Biowulf cluster (http://hpc.nih.gov).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written consent was obtained for human research subjects, as approved by the NIH Institutional Review Board (protocol # NCT02659943).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesYes ER -